Rob A E M Tollenaar
Overview
Explore the profile of Rob A E M Tollenaar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
247
Citations
10622
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Morra A, Schreurs M, Andrulis I, Anton-Culver H, Augustinsson A, Beckmann M, et al.
Cancer Med
. 2023 Jul;
12(15):16142-16162.
PMID: 37401034
Background: Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC-specific survival (BCSS) compared to non-carriers. Aim: To assessed...
12.
Moran A, Elgood-Hunt G, van der Burgt Y, Wuhrer M, Mesker W, Tollenaar R, et al.
Biomolecules
. 2023 Jun;
13(6).
PMID: 37371476
A newly developed analytical strategy was applied to profile the total serum -glycome of 64 colorectal cancer (CRC) patients before and after surgical intervention. In this cohort, it was previously...
13.
van Kooten R, Schutte B, van Staalduinen D, Hoeksema J, Holman F, van Dorp C, et al.
Colorectal Dis
. 2023 Jun;
25(8):1578-1587.
PMID: 37329241
Background: Colorectal cancer is diagnosed in approximately 500,000 patients each year in Europe, leading to a high number of patients having to cope with the consequences of resection for colorectal...
14.
Roelands J, Kuppen P, Ahmed E, Mall R, Masoodi T, Singh P, et al.
Nat Med
. 2023 May;
29(5):1273-1286.
PMID: 37202560
The lack of multi-omics cancer datasets with extensive follow-up information hinders the identification of accurate biomarkers of clinical outcome. In this cohort study, we performed comprehensive genomic analyses on fresh-frozen...
15.
van Kooten R, Algie J, Tollenaar R, Wouters M, Putter H, Peeters K, et al.
Eur J Surg Oncol
. 2023 Apr;
49(9):106914.
PMID: 37105868
Background: As the survival of patients with rectal cancer has improved in recent decades, more and more patients have to live with the consequences of rectal cancer surgery. An influential...
16.
Zhang X, Gunda A, Meershoek-Klein Kranenbarg E, Liefers G, Savitha B, Shrivastava P, et al.
Breast Cancer Res
. 2023 Apr;
25(1):40.
PMID: 37060036
Background: Hormone receptor (HR)-positive, HER2/neu-negative breast cancers have a sustained risk of recurrence up to 20 years from diagnosis. TEAM (Tamoxifen, Exemestane Adjuvant Multinational) is a large, multi-country, phase III...
17.
Hoeijmakers F, Schreurs W, Comans E, Belderbos J, Postmus P, Tollenaar R, et al.
J Thorac Oncol
. 2023 Apr;
17(11):1250-1254.
PMID: 37014165
No abstract available.
18.
Fan C, Wang Q, Kuipers T, Cats D, Iyengar P, Hagenaars S, et al.
EMBO J
. 2023 Mar;
42(10):e112806.
PMID: 36994542
Epithelial cells acquire mesenchymal phenotypes through epithelial-mesenchymal transition (EMT) during cancer progression. However, how epithelial cells retain their epithelial traits and prevent malignant transformation is not well understood. Here, we...
19.
Morra A, Schreurs M, Andrulis I, Anton-Culver H, Augustinsson A, Beckmann M, et al.
Res Sq
. 2023 Feb;
PMID: 36824750
Breast cancer (BC) patients with a germline c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC-specific survival (BCSS) compared to non-carriers. We aimed to assess the...
20.
Smit M, Ciompi F, Bokhorst J, van Pelt G, Geessink O, Putter H, et al.
J Pathol Inform
. 2023 Feb;
14:100191.
PMID: 36794267
Background: The amount of stroma within the primary tumor is a prognostic parameter for colon cancer patients. This phenomenon can be assessed using the tumor-stroma ratio (TSR), which classifies tumors...